<!DOCTYPE html
  PUBLIC "-//W3C//DTD HTML 4.01//EN">
<html xmlns:gc="http://docs.oasis-open.org/codelist/ns/genericode/1.0/"><head xmlns="http://www.w3.org/1999/xhtml"><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"></meta><meta charset="utf-8"></meta><meta name="viewport" content="width=device-width, initial-scale=1"></meta><meta http-equiv="X-UA-Compatible" content="IE=10"></meta><meta name="documentId" content="df363dae-0612-4be7-bb92-a8381fa1da35"></meta><meta name="documentSetId" content="aeb4ec67-8764-4b72-b7a5-0bae88db11a3"></meta><meta name="documentVersionNumber" content="3"></meta><meta name="documentEffectiveTime" content="20180101"></meta><title>LORUM IPSUM (acetaminophen), TABLET, CAPSULE, POWDER</title><link href="http://canada.ca/etc/designs/canada/wet-boew/assets/favicon.ico" rel="icon" type="image/x-icon"> </link><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/css/bootstrap.min.css" integrity="sha384-Vkoo8x4CGsO3+Hhxv8T/Q5PaXtkKtu6ug5TOeNV6gBiFeWPGFN9MuhOf23Q9Ifjh" crossorigin="anonymous"> </link><link rel="stylesheet" href="https://cease353.github.io/xtest/current/spl_canada.css"> </link><style>
				/* ScrollSpy, Stickiness/Affix, and French Navigation Reduction */
			  
				html {
/* disable smooth scrolling
					scroll-behavior: smooth;
*/
				}
								
				.sticky {
					position: -webkit-sticky;
					position: sticky;
					top: 0;
				}

				
				</style></head><body data-spy="scroll" data-target="#navigation-sidebar" data-offset="1"><div class="bg-aurora-accent1 hide-in-print"><h2 class="text-white text-center p-2">LORUM IPSUM (acetaminophen), TABLET, CAPSULE, POWDER</h2></div><div class="container-fluid position-relative" id="content"><div class="row h-100"><aside xmlns="http://www.w3.org/1999/xhtml" class="hide-in-print mb-2" id="left"><div class="sticky-top sticky d-none d-md-block hide-in-print" id="side"><section class="card"><h5 class="card-header text-white bg-aurora-accent1">TABLE OF CONTENTS</h5><div style="transform: scaleX(-1);" id="navigation-scrollbar"><ul class="navbar-nav" id="navigation-sidebar" style="transform: scaleX(-1); "><li class="nav-item"><a href="#drop-bdeefc11-4315-41e3-8c56-83e8bf4f770b" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PRODUCT DETAILS</a><ul id="drop-bdeefc11-4315-41e3-8c56-83e8bf4f770b" class="navbar-nav small collapse"><li class="nav-item"><a href="#company-details" class="nav-link active">COMPANY DETAILS</a></li><li class="nav-item"><a href="#product-1" class="nav-link">Product #1 LORUM IPSUM POWDER 
		(acetaminophen), 		
		ACETAMINOPHEN&nbsp;
			1&nbsp;								
			mg&nbsp;
		POWDER FOR ORAL SOLUTION</a></li></ul></li><li class="nav-item"><a href="#eed00b53-cdb2-4aa6-9e82-88b7d793b208" class="nav-link nav-top">TITLE PAGE</a></li><li class="nav-item"><a href="#dd1e1c43-f0d3-4ba8-b1f5-ad009a5dd5a8" class="nav-link nav-top">RECENT MAJOR LABEL CHANGES</a></li><li class="nav-item"><a href="#drop-e6bb83b9-2602-4f96-9077-b8b9535c254e" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART I: HEALTH PROFESSIONAL INFORMATION</a><ul id="drop-e6bb83b9-2602-4f96-9077-b8b9535c254e" class="navbar-nav small collapse"><li class="nav-item"><a href="#c2ea4fad-2b79-4dbc-8d99-6843adc2dec8" class="nav-link">1 INDICATIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#f2aa7e0e-2042-4a4c-a783-9ad4e8717a32" class="nav-link">1.1 Pediatrics</a></li><li class="nav-item"><a href="#be75cfb9-3132-4903-800b-267427388a13" class="nav-link">1.2 Geriatrics</a></li></ul></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-367427388a13" class="nav-link">2 CONTRAINDICATIONS</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267427398a13" class="nav-link">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267727398a13" class="nav-link">4 DOSAGE AND ADMINISTRATION</a><ul class="navbar-nav"><li class="nav-item"><a href="#be75cfb9-3131-4103-800b-267727398a13" class="nav-link">4.1 Dosing Considerations</a></li><li class="nav-item"><a href="#b3d876c1-c36c-4ed5-8993-c507e3ab9f2e" class="nav-link">4.2 Recommended Dose and Dosage Adjustment</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f3a" class="nav-link">4.3 Reconstitution</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f4a" class="nav-link">4.4 Administration</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63d33a5-e08a-472c-b8a2-b12dbc115f7a" class="nav-link">4.4.1 Image Acquisition and Interpretation</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f5a" class="nav-link">4.5 Missed Dose</a></li><li class="nav-item"><a href="#a63c13a5-e08a-472c-b8a2-a12dba105f5a" class="nav-link">4.6 Radiation Dosimetry</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbc114f7a" class="nav-link">4.6.1 Physical Characteristics</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b7a2-b12dbc115f7a" class="nav-link">4.6.2 External Radiation</a></li></ul></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f6a" class="nav-link">5 OVERDOSAGE</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f7a" class="nav-link">6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba115f7a" class="nav-link">7 WARNINGS AND PRECAUTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dbc115f7a" class="nav-link">7.1 Special Populations</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbc115f7a" class="nav-link">7.1.1 Pregnant Women</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbd115f7a" class="nav-link">7.1.2 Breast-feeding</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8c2-b12dbc115f7a" class="nav-link">7.1.3 Pediatrics</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8d2-b12dbc115f7a" class="nav-link">7.1.4 Geriatrics</a></li></ul></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b22dbc115f7a" class="nav-link">8 ADVERSE REACTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbd215f7a" class="nav-link">8.1 Adverse Reaction Overview</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472e-b8c2-b12dbc115f7a" class="nav-link">8.1.1 Immunogenicity</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b12dbd215f7a" class="nav-link">8.2 Clinical Trial Adverse Reactions</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c45a5-e08a-472e-b8c2-b12dbc115f7a" class="nav-link">8.2.1 Clinical Trial Adverse Reactions - Pediatrics (if applicable)</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b12dbd315f7a" class="nav-link">8.3 Less Common Clinical Trial Adverse Reactions</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c45a5-e08a-472e-b8c2-b12dbc115f1a" class="nav-link">8.3.1 Less Common Clinical Trial Adverse Reactions - Pediatrics (if applicable)</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b22dbd215f7a" class="nav-link">8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63ca5a5-e08a-472e-b8c2-b12dbc115f1a" class="nav-link">8.4.1 Clinical Trial Findings</a></li><li class="nav-item"><a href="#a62ca5a5-e08a-472e-b8c2-b12dbc115f1a" class="nav-link">8.4.2 Post-Market Findings</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b32dbd215f7a" class="nav-link">8.5 Post-Market Adverse Reactions</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63ca5a5-e08a-472e-b8c2-b12dbc995f1a" class="nav-link">8.5.1 Post-Market Adverse Reaction in Adults</a></li><li class="nav-item"><a href="#a62ca5a5-e08a-472e-b8c2-b12d48115f1a" class="nav-link">8.5.2 Post-Market Adverse Reactions in Pediatrics (if applicable)</a></li></ul></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-483c-b8a2-b22dbd215f7a" class="nav-link">9 DRUG INTERACTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b14dbd315f7a" class="nav-link">9.1 Drug Interactions Overview</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267527398a13" class="nav-link">9.2 Serious Drug Interactions Box</a></li><li class="nav-item"><a href="#a63c56a5-e08a-473c-b8a2-b14dbd315f7a" class="nav-link">9.3 Drug-Behavioural Risk</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8d2-b14dbd315f7a" class="nav-link">9.4 Drug-Drug Interactions</a></li><li class="nav-item"><a href="#a63c33a5-e0aa-473c-b8a2-b14dbd315f7a" class="nav-link">9.5 Drug-Food Interactions</a></li><li class="nav-item"><a href="#a63c33a5-e08a-47bc-b8d2-b14dbd315f7a" class="nav-link">9.6 Drug-Herb Interactions</a></li><li class="nav-item"><a href="#be78cfb9-3131-4903-800b-267527398a13" class="nav-link">9.7 Drug-Laboratory Test Interactions</a></li></ul></li><li class="nav-item"><a href="#fa324c26-b939-4c3a-901d-516ccc314522" class="nav-link">10 ACTION AND CLINICAL PHARMACOLOGY</a><ul class="navbar-nav"><li class="nav-item"><a href="#f7a324c26-b939-4c3a-901e-516ccc314522" class="nav-link">10.1 Mechanism of Action</a></li><li class="nav-item"><a href="#da324c26-b939-4d3a-901e-516ccc314522" class="nav-link">10.2 Pharmacodynamics</a></li><li class="nav-item"><a href="#aaa324c26-b939-4d4a-901e-516ccc314522" class="nav-link">10.3 Pharmacokinetics</a></li></ul></li><li class="nav-item"><a href="#da324d26-c939-443a-901e-526dcc314522" class="nav-link">11 STORAGE, STABILITY AND DISPOSAL</a></li><li class="nav-item"><a href="#bba325d26-c939-443a-901e-526dcc314522" class="nav-link">12 SPECIAL HANDLING INSTRUCTIONS</a></li></ul></li><li class="nav-item"><a href="#drop-d91389e0-c234-44d9-8327-91b121723a8f" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART II: SCIENTIFIC INFORMATION</a><ul id="drop-d91389e0-c234-44d9-8327-91b121723a8f" class="navbar-nav small collapse"><li class="nav-item"><a href="#ee2875272-8229-4c12-919e-827854dcd76a" class="nav-link">13 PHARMACEUTICAL INFORMATION</a></li><li class="nav-item"><a href="#ab2875272-8229-4c12-919e-827854ddd76a" class="nav-link">14 CLINICAL TRIALS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a2875272-8229-4c12-919e-827854ddd78a" class="nav-link">14.1 Trial Design and Study Demographics</a></li><li class="nav-item"><a href="#a2875272-8229-4a12-919e-827854ddd78a" class="nav-link">14.2 Study Results</a></li><li class="nav-item"><a href="#df2875272-8229-4c12-919e-827954ddd78a" class="nav-link">14.3 Comparative Bioavailability Studies</a></li></ul></li><li class="nav-item"><a href="#a2875272-8229-4c12-a19e-827954ddd78a" class="nav-link">15 MICROBIOLOGY</a></li><li class="nav-item"><a href="#a42a7572-8229-4c12-a19e-827954ddd78a" class="nav-link">16 NON-CLINICAL TOXICOLOGY</a></li><li class="nav-item"><a href="#ef8a4d48-0fc3-4e44-b4b6-550140d4de5d" class="nav-link">17 SUPPORTING PRODUCT MONOGRAPHS</a></li></ul></li><li class="nav-item"><a href="#drop-be74b6e6-c461-4a5f-a18e-ed321b381456" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PATIENT MEDICATION INFORMATION</a><ul id="drop-be74b6e6-c461-4a5f-a18e-ed321b381456" class="navbar-nav small collapse"><li class="nav-item"><a href="#ea4ec98b-b2d3-4d73-877c-aaa5eb28997d" class="nav-link">READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE</a></li><li class="nav-item"><a href="#baa4d498-0gc3-4e44-bcb6-550140d4de5d" class="nav-link">What is [Brand name] used for?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e44-bcb6-550140d4de5d" class="nav-link">How does [Brand name] work?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e44-bcb6-55013024de5d" class="nav-link">What are the ingredients in [Brand name]?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e54-bcb6-550130d4de5d" class="nav-link">[Brand name] comes in the following dosage forms:</a></li><li class="nav-item"><a href="#bca4c498-00c3-4e44-bcb6-550134d4de5d" class="nav-link">Do not use [Brand name] if:</a></li><li class="nav-item"><a href="#b6b37351-bbc9-46d9-b148-27ba3cb0a75e" class="nav-link">To help avoid side effects and ensure proper use, talk to your healthcare professional before you take [Brand name]]. Talk about any health conditions or problems you may have, including if you:</a></li><li class="nav-item"><a href="#edac0d6f-3c91-48b5-99c0-e0f940925d37" class="nav-link">Other warnings you should know about:</a></li><li class="nav-item"><a href="#bca4c498-0ac3-4e44-bcb6-550134d4de5d" class="nav-link">The following may interact with [Brand name]:</a></li><li class="nav-item"><a href="#e23321cd-5111-4aa3-b650-74f93bcda261" class="nav-link">How to take [Brand name]:</a></li><li class="nav-item"><a href="#cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7" class="nav-link">Usual dose:</a></li><li class="nav-item"><a href="#beaaa5b8-6693-4d4c-a897-fa5c9562b1be" class="nav-link">Overdose:</a></li><li class="nav-item"><a href="#ffd59b8d-fe66-4d86-a54f-0613d4168199" class="nav-link">Missed dose:</a></li><li class="nav-item"><a href="#cb61f530-b95a-4047-b8ea-861c5a7a05e8" class="nav-link">What are possible side effects from using [Brand name]?</a></li><li class="nav-item"><a href="#c9d75711-2ce9-451e-aa51-91026ec1555e" class="nav-link">Storage:</a></li><li class="nav-item"><a href="#f6693e7a-21c9-492f-833b-4e8f3911d3a5" class="nav-link">If you want more information about [Brand name]:</a></li></ul></li></ul></div></section></div></aside><main class="col"><div class="container-fluid" id="main"><div class="row position-relative"><div class="col"><div class="card mb-2 hide-in-print" id="bdeefc11-4315-41e3-8c56-83e8bf4f770b"><h5 class="card-header text-white bg-aurora-accent1">PRODUCT DETAILS</h5><div id="product-accordion"><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="company-details"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-company-details" aria-expanded="true" aria-controls="collapse-company-details">COMPANY DETAILS</button></h6><div id="collapse-company-details" class="collapse show spl" data-parent="#product-accordion"><table xmlns="" width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Market Authorization Holder -&nbsp;</span>Acme Pharma Inc. (1111)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>9526 Columbia St.</td></tr><tr><td>Hanover Park,&nbsp;Illinois,&nbsp;60133</td></tr><tr><td>UNITED STATES OF AMERICA (THE)</td></tr></table></td><td class="formItem"><div>Tel: +12025550178</div><div>Email: test@canada.ca</div><div>Web: http://www.test.ca</div></td></tr></table><table xmlns="" width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Canadian Importer/Distributor -&nbsp;</span>Acme Distributing Ltd. (0000)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>250 Lanark Ave.</td></tr><tr><td>Ottawa,&nbsp;Ontario,&nbsp;K1Z 6R5</td></tr><tr><td>CANADA</td></tr></table></td><td class="formItem"><div>Tel: +14165550134</div><div>Email: test.2@canada.ca</div><div>Web: http://www.test.ca</div></td></tr></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-1"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-1" aria-expanded="true" aria-controls="collapse-product-1">Product #1 LORUM IPSUM POWDER 
		(acetaminophen), 		
		ACETAMINOPHEN&nbsp;
			1&nbsp;								
			mg&nbsp;
		POWDER FOR ORAL SOLUTION</button></h6><div id="collapse-product-1" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM POWDER&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen powder for oral solution</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM POWDER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">65432551</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">SUBCUTANEOUS USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">POWDER FOR ORAL SOLUTION</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">1&nbsp;								
			mg&nbsp;in&nbsp;5&nbsp;mL</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (OFF WHITE)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">THYROID AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1212<br><br><br></td><td class="formItem">1 &nbsp;in&nbsp;1 BOX<br>2 &nbsp;in&nbsp;1 TRAY<br>5 mL&nbsp;in&nbsp;1 VIAL<br></td><td class="formItem">APPROVED<br><br><br></td><td class="formItem">2018-06-01<br><br><br></td><td class="formItem"><br><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section></div></div><div class="card mb-2 force-page-break-after" id="eed00b53-cdb2-4aa6-9e82-88b7d793b208"><h5 class="card-header text-white bg-aurora-accent1 hide-in-print">TITLE PAGE</h5><div class="spl title-page title-page-row"><p class="First"> Scheduling Symbol, Brand Name, Proper name, Dosage
                                    Form(s), Strength(s) and Route(s) of Administration,
                                    Pharmaceutical Standard, Therapeutic Classification </p><p>For products which have been authorized under the Notice of Compliance with Conditions (NOC/c) policy, include the following boxed statement:</p><table width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">"&lt;Brand name&gt;, indicated for:<br>- [ ]<br>
                                                    has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for &lt;Brand name&gt; please refer to Health Canada’s <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/notice-compliance-conditions.html">Notice of Compliance with conditions - drug products web site.</a>"<br>
                                                    [For market authorizations without conditions]<br>
                                                    "[Brand name] indicated for:<br>
                                                    - [ ]<br>
                                                    has been issued marketing authorization without conditions."
                                                
                                                
                                                </p></td></tr></tbody></table></div><div class="spl title-page-row title-page-rule"><div class="title-page-left"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0tp1.2" id="f187daf9-5e75-425a-9de6-f6ce1af2a965"><a name="ac26f58c-721a-4c51-8bbc-c9dddb1f1233"> </a><a name="section-2.2"> </a><p></p><h2 xmlns="">Company Name and Address</h2><p xmlns="" class="First"> Company Name<br> Street address<br> City<br>
                                    Province<br> Postal code<br></p></div><div xmlns="http://www.w3.org/1999/xhtml" class="Section"><br></br><h2 style="display: inline;">Submission Control Number: </h2>123456</div></div><div class="title-page-right"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0tp1.3" id="bf2dab4e-fd04-4ec9-9cdc-247188622d0f"><a name="e5f1dea3-d907-4664-b46f-e1d9736d47af"> </a><a name="section-2.3"> </a><p></p><h2 xmlns="">Date of Initial Approval</h2><p xmlns="" class="First">December 20, 2019</p></div><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0tp1.4" id="d0184119-8fd7-4378-af77-b227c39e8445"><a name="ad78301c-29a9-41af-96f8-d58815fed296"> </a><a name="section-2.4"> </a><p></p><h2 xmlns="">Date of Revision</h2><p xmlns="" class="First">December 20, 2019</p></div></div></div><div class="spl title-page title-page-row"><p class="First">[BRAND NAME<span class="Sup">®</span> or ™] is a registered
                                    trademark of [COMPANY]</p></div></div><div class="card mb-2" id="dd1e1c43-f0d3-4ba8-b1f5-ad009a5dd5a8"><h5 class="card-header text-white bg-aurora-accent1">RECENT MAJOR LABEL CHANGES</h5><div class="spl recent-changes"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="1RMLC" id="d7cee5c8-7ee9-4fd2-884e-7a50c06b27e1"><a name="dd1e1c43-f0d3-4ba8-b1f5-ad009a5dd5a8"> </a><a name="section-3"> </a><p></p><h1 xmlns="">RECENT MAJOR LABEL CHANGES</h1><a xmlns="" name="t6"></a><table xmlns="" width="100%"><tbody class="Headless"><tr class="First"><td>Indications (1)</td><td>05/2018</td></tr><tr><td>Indications, Pediatrics (1.1)</td><td>05/2018</td></tr><tr><td>Contraindications (2)</td><td>04/2018</td></tr><tr><td>Serious Warning and Precautions Box (3), Lactic Acidosis and
                                        Severe Hepatomegaly with Steatosis [Removed]</td><td>05/2018</td></tr><tr><td>Dosage and Administration, Recommended Dose and Dose
                                        Adjustment (4.3)</td><td>08/2018</td></tr><tr class="Last"><td>Warnings and Precautions, Endocrine and Metabolism (7)</td><td>05/2018</td></tr></tbody></table></div></div></div><div class="card mb-2 pb-2" id="e6bb83b9-2602-4f96-9077-b8b9535c254e"><h5 class="card-header text-white bg-aurora-accent1">PART I: HEALTH PROFESSIONAL INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="pi00" id="d6a947eb-e2be-45c0-8b2e-15d0d0eebea8"><a name="e6bb83b9-2602-4f96-9077-b8b9535c254e"> </a><a name="section-4"> </a><p></p><h1 xmlns="">PART I: HEALTH PROFESSIONAL INFORMATION</h1><div class="Section" data-sectionCode="pi01" id="c2ea4fad-2b79-4dbc-8d99-6843adc2dec8"><a name="aa3f869a-7734-425a-85d8-b8bd4d3500a5"> </a><a name="section-4.1"> </a><p></p><h2 xmlns="">1 INDICATIONS</h2><p xmlns="" class="First">[Indications have been granted on the basis of similarity between &lt;Biosimilar brand name&gt; and the reference biologic drug &lt;Reference biologic drug brand name&gt;.]</p><p xmlns="">[[Biosimilar] Brand name (proper name)] is indicated for:</p><ul xmlns=""><li>[text]</li><li>[text]</li></ul><p xmlns="">[The wording of each indication authorized for the biosimilar should be identical to the reference biologic drug product monograph.]</p><p xmlns="">[Include a brief discussion of any promising clinical information.]</p><p xmlns="">[text]</p><div class="Section" data-sectionCode="pi01.1" id="f2aa7e0e-2042-4a4c-a783-9ad4e8717a32"><a name="b9db4ce0-3f46-434a-bd7b-4a3e010adaad"> </a><a name="section-4.1.1"> </a><p></p><h3 xmlns="">1.1 Pediatrics</h3><p xmlns="" class="First">[One of the following or similar statements should be
                                            used:]</p><p xmlns=""><span class="Bold">Pediatrics [(age range)]:</span>Based on the data submitted, the safety and efficacy of [Brand name] in pediatric patients has been established; therefore, Health Canada has authorized an indication for pediatric use. [(cross-reference to relevant sections)]</p><p xmlns="">[or]</p><p xmlns=""><span class="Bold">Pediatrics [(age range)]:</span>Insufficient data are available therefore, Health Canada has not authorized an indication for pediatric use.</p></div><div class="Section" data-sectionCode="pi01.2" id="be75cfb9-3132-4903-800b-267427388a13"><a name="b9db4be0-3f46-43fa-bd7b-4a3e010adaad"> </a><a name="section-4.1.2"> </a><p></p><h3 xmlns="">1.2 Geriatrics</h3><p xmlns="" class="First">[One of the following or similar statements may be used:]</p><p xmlns=""><span class="Bold">Geriatrics [(&gt; x years of age)]:</span> Insufficient data are available therefore, Health Canada has not authorized an indication for geriatric use.</p><p xmlns="">[or]</p><p xmlns=""><span class="Bold">Geriatrics [(&gt; x years of age)]:</span>
                                            Evidence from clinical studies and experience suggests that use in the
                                            geriatric population is associated with differences in safety or
                                            effectiveness.</p></div></div><div class="Section" data-sectionCode="pi02" id="be75cfb9-3131-4903-800b-367427388a13"><a name="b90b4be0-3f46-437a-bd7b-4a3e010adaad"> </a><a name="section-4.2"> </a><p></p><h2 xmlns="">2 CONTRAINDICATIONS</h2><p xmlns="" class="First">[Proper name] is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Dosage Forms, Strengths, Composition and Packaging (6); evidence regarding the risk of teratogenicity following exposure; should exposure during pregnancy occur the following steps should be taken e.g. discontinue drug, ultrasound, monitor neonate for hypotension; cross-reference to Pregnancy and Patient Medication Information.]</p><ul xmlns=""><li>[text]</li><li>[text]</li></ul></div><div class="Section" data-sectionCode="pi03" id="be75cfb9-3131-4903-800b-267427398a13"><a name="b9fb4be0-3f46-437a-bd7b-4a3e010adaad"> </a><a name="section-4.3"> </a><p></p><h2 xmlns="">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</h2><p xmlns="" class="First">[Cytotoxic, or non-cytotoxic but hazardous drugs should be identified here, with cross-reference to disposal (11 STORAGE, STABILITY AND DISPOSAL) and special handling instructions (12 SPECIAL HANDLING INSTRUCTIONS); generally, information in this box should be replicated in the Patient Medication Information.]</p><p xmlns="">[In the absence of a serious warning or precaution, maintain the heading but delete the box, and the following statement should be made:]</p><p xmlns="">At this time, no serious warnings or precautions have been identified.</p><table xmlns="" width="100%"><caption><span>Serious Warnings and Precautions</span></caption><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">[Clinically significant or serious (i.e. life-threatening) safety hazards should be placed in this box, with a cross reference to the relevant section(s) for more detailed information e.g. acute hepatic failure, infusion reaction. Generally not to exceed 20 lines]</p><ul><li>[text]</li><li>[text]</li></ul></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04" id="be75cfb9-3131-4903-800b-267727398a13"><a name="b9db4be0-3f46-434a-bd7b-4a3e010adaad"> </a><a name="section-4.4"> </a><p></p><h2 xmlns="">4 DOSAGE AND ADMINISTRATION</h2><div class="Section" data-sectionCode="pi04.1" id="be75cfb9-3131-4103-800b-267727398a13"><a name="b9db4be0-3f46-437a-bd7b-4a3e310adaad"> </a><a name="section-4.4.1"> </a><p></p><h3 xmlns="">4.1 Dosing Considerations</h3><p xmlns="" class="First">[Briefly list all situations that may affect dosing of the drug e.g. renal disease, concomitant therapy, changing from intravenous to oral therapy, lab values prior to infusion, rule out pregnancy prior to administration, pre-medication is required, duration of effect, imaging time post-injection.]</p><p xmlns="">[Identify any safety monitoring procedures that should be implemented before initiating or during therapy to determine how to administer drug e.g. stop drug, adjust dosage, delay additional course; must include steps that should be taken to prevent or mitigate clinically significant adverse reactions in Warnings and Precautions section.)]</p><ul xmlns=""><li>[text]</li></ul></div><div class="Section" data-sectionCode="pi04.2" id="b3d876c1-c36c-4ed5-8993-c507e3ab9f2e"><a name="da2d22a3-b5c2-4a62-b138-9594dd0491bb"> </a><a name="section-4.4.2"> </a><p></p><h3 xmlns="">4.2 Recommended Dose and Dosage Adjustment</h3><p xmlns="" class="First">[For drugs with multiple indications, this section should be clear as to which information applies to which particular indication. Include dosages for each indication, route of administration and/or dosage form, dosage schedules, booster doses, initial dose, titration of dose, dosage range, maximum daily dose, maintenance dosage, duration of treatment and drug discontinuance, considerations for special populations. For example:</p><p xmlns="">Administer 40 mg of [drug] oral solution orally every 12 hours. Avoid intravenous administration [see Warnings and Precautions, Cardiovascular (7.0)]</p><p xmlns="">With concomitant use of [drug] with strong CYP3A4 inhibitors decrease the [drug] dosage to 30 mg once daily [see Drug Interactions (9.4)]. No dosage adjustment is needed for moderate CYP3A4 inhibitors.]</p><p xmlns="">[text]</p><p xmlns="">[In the absence of a Health Canada authorized pediatric indication, the following statement should be used:]</p><p xmlns="">Health Canada has not authorized an indication for pediatric use.</p></div><div class="Section" data-sectionCode="pi04.3" id="a63c33a5-e08a-472c-b8a2-a12dba105f3a"><a name="a473c162-f176-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.4.3"> </a><p></p><h3 xmlns="">4.3 Reconstitution</h3><p xmlns="" class="First"><span class="Bold">Oral Solutions:</span></p><p xmlns="">[List recommended diluents for reconstitution; directions should include the volume and type of diluents to be added and the approximate volume and concentration of the resulting product]</p><p xmlns="">[Recommended storage period and conditions should be stated and include cross-reference to Storage, Stability and Disposal.]</p><p xmlns="">[text and/or table]</p><p xmlns=""><span class="Bold">Parenteral Products:</span> [table and text]</p><table xmlns="" width="100%"><caption><span>Table - Reconstitution</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Vial Size</th><th class="Botrule Lrule Rrule Toprule">Volume of Diluent to be Added to Vial</th><th class="Botrule Lrule Rrule Toprule">Approximate Available Volume</th><th class="Botrule Lrule Rrule Toprule">Concentration per mL</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td></tr></tbody></table><p xmlns="">[Include any specific precautions, storage periods and incompatibilities.][For intravenous use, information should be separately described for direct intravenous injection, intermittent infusion, and continuous infusion.]</p></div><div class="Section" data-sectionCode="pi04.4" id="a63c33a5-e08a-472c-b8a2-a12dba105f4a"><a name="a473c162-e176-44d0-b797-2b7b6cf0ae43"> </a><a name="section-4.4.4"> </a><p></p><h3 xmlns="">4.4 Administration</h3><p xmlns="" class="First">[Special consideration e.g. do not crush, do not split if not scored, if capsule contents can be sprinkled, timing of dose with respect to food such as should not be taken with milk/ food, duration of effect (see Recommended Dose (4.2), special handling e.g. not to be directly administered to the patient (see Special Handling (12)), in-line filter is required]</p><p xmlns="">[text and/or table]</p><div class="Section" data-sectionCode="pi04.4.1" id="a63d33a5-e08a-472c-b8a2-b12dbc115f7a"><a name="a473c122-e176-4ad0-b797-2b7b6cf00e43"> </a><a name="section-4.4.4.1"> </a><p></p><h4 xmlns="">4.4.1 Image Acquisition and Interpretation</h4><p xmlns="" class="First">[text]</p></div></div><div class="Section" data-sectionCode="pi04.5" id="a63c33a5-e08a-472c-b8a2-a12dba105f5a"><a name="a473c162-e176-44d0-b797-2b7b6cf00e33"> </a><a name="section-4.4.5"> </a><p></p><h3 xmlns="">4.5 Missed Dose</h3><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi04.6" id="a63c13a5-e08a-472c-b8a2-a12dba105f5a"><a name="a473c162-e176-44d0-b797-2b7b6cf10e33"> </a><a name="section-4.4.6"> </a><p></p><h3 xmlns="">4.6 Radiation Dosimetry</h3><p xmlns="" class="First">[Presentation of Dose Estimate Data. Include dosimetry information for both the patient receiving the drug and the person preparing or administering the drug:]</p><p xmlns="">Final Dose Estimates: [The model and method of calculation should be specified.]</p><a xmlns="" name="t4.6"></a><table xmlns="" width="100%"><tbody class="Headless"><tr class="First" align="center"><th class="Botrule Lrule Rrule Toprule">ORGAN</th><th class="Botrule Lrule Rrule Toprule">mGy/MBq</th><th class="Botrule Lrule Rrule Toprule">rad/mCi</th></tr><tr><td class="Botrule Lrule Rrule Toprule">Adrenals</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Brain</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Breasts</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Gallbladder Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">LLI Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Small Intestine</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Stomach</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">ULI Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Heart Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Kidneys</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Liver</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Lungs</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Muscle</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Ovaries</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Pancreas</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Red Marrow</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Bone Surfaces</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Skin</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Spleen</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Testes</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Thymus</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Thyroid</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Urinary Bladder</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">Uterus</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="">Effective Dose Equivalent (mSv/MBq) (rem/mCi)</p><p xmlns="">Effective Dose (mSv/MBq) (rem/mCi)</p><div class="Section" data-sectionCode="pi04.6.1" id="a63c33a5-e08a-472c-b8a2-b12dbc114f7a"><a name="a473c162-e176-4ad0-b797-2b7c6cf00e43"> </a><a name="section-4.4.6.1"> </a><p></p><h4 xmlns="">4.6.1 Physical Characteristics</h4><p xmlns="" class="First">[Physical half-live, principle radiation emission data, physical decay chart (tabular format), parent and daughter radionuclides data]</p></div><div class="Section" data-sectionCode="pi04.6.2" id="a63c33a5-e08a-472c-b7a2-b12dbc115f7a"><a name="a473c162-e176-4dd0-b797-2b7b6cf00e43"> </a><a name="section-4.4.6.2"> </a><p></p><h4 xmlns="">4.6.2 External Radiation</h4><p xmlns="" class="First">[Physical half-live, principle radiation emission data, physical decay chart (tabular format), parent and daughter radionuclides data]</p></div></div></div><div class="Section" data-sectionCode="pi05" id="a63c33a5-e08a-472c-b8a2-a12dba105f6a"><a name="a473c162-e176-44d0-b797-2b7b6cf20e43"> </a><a name="section-4.5"> </a><p></p><h2 xmlns="">5 OVERDOSAGE</h2><p xmlns="" class="First">[Describe acute symptoms and signs and potential sequelae, and current management of overdose including clinical interventions, monitoring, use of agonist/ antagonist/ antidote, method to increase elimination.]</p><p xmlns="">[Consider special populations (i.e. elderly, hepatic impairment) and pediatrics for which product/ strength for which ingestion of only one dose unit can cause fatal poisoning.]</p><p xmlns="">[For example: Frequently observed symptoms of overdose are nausea, vomiting, anemia and nephrotoxicity. No specific antidote exists. Discontinue therapy immediately. Hemodialysis may be indicated.]</p><p xmlns="">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">For management of a suspected drug overdose, contact your regional poison control centre.</td></tr></tbody></table></div><div class="Section" data-sectionCode="pi06" id="a63c33a5-e08a-472c-b8a2-a12dba105f7a"><a name="a471c162-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.6"> </a><p></p><h2 xmlns="">6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</h2><a xmlns="" name="t5"></a><table xmlns="" width="100%"><caption><span>Table - Dosage Forms, Strenghts, Composition and Packaging.</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Route of Administration </th><th class="Botrule Lrule Rrule Toprule">Dosage Form / Strength / Composition </th><th class="Botrule Lrule Rrule Toprule">Non-medicinal Ingredients</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[oral]</td><td class="Botrule Lrule Rrule Toprule">[tablet 5 mg, 10 mg]</td><td class="Botrule Lrule Rrule Toprule">[List all non-medicinal
                                                ingredients in alphabetical order.]</td></tr></tbody></table><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi07" id="a63c33a5-e08a-472c-b8a2-a12dba115f7a"><a name="a4731162-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.7"> </a><p></p><h2 xmlns="">7 WARNINGS AND PRECAUTIONS</h2><p xmlns="" class="First">[If applicable, include one the following statements:]</p><p xmlns="">Please see the Serious Warnings and Precautions Box at the beginning of Part I: Health Professional Information.</p><p xmlns="">[For blood products]</p><p xmlns="">This product is prepared from large pools of human plasma. Thus, there is a possibility it may contain causative agents of viral or other undetermined diseases.</p><p xmlns="">[In order to improve traceability of biological medicinal products, the tradename and batch number of the administered product should be clearly recorded (or stated) in the patient file.]</p><p xmlns="">[Subheadings to be included as applicable, in alphabetical order:]</p><p xmlns=""><span class="Bold">General</span><br>[text]<br></p><p xmlns=""><span class="Bold">Carcinogenesis and Mutagenesis</span><br>[This section should generally include only human data where there is evidence that the drug is carcinogenic or mutagenic. Where there is only animal data, a cross-reference to the animal data in the Non-clinical Toxicology section should be provided]<br>[text]<br></p><p xmlns=""><span class="Bold">Cardiovascular</span><br>[As per Dosage and Administration example above: Cases of clinically significant hypotension occurred with inappropriate administration of &lt;drug&gt; oral solution intravenously. Some cases require fluids and pressor agents. Administer &lt;drug&gt; oral solution only by the oral route and avoid intravenous administration of &lt;drug&gt;.]<br>[text]<br></p><p xmlns=""><span class="Bold">Dependence/Tolerance</span><br>[include effects resulting from both physical and psychological dependence.]<br>[text]<br></p><p xmlns=""><span class="Bold">Driving and Operating Machinery</span><br>[This subheading should include the following or similar statement:]<br>Due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery.</p><p xmlns=""><span class="Bold">Ear/Nose/Throat</span><br>[text]<br></p><p xmlns=""><span class="Bold">Endocrine and Metabolism</span><br>[This subheading should specify genetic polymorphism where applicable.]<br>[text]<br></p><p xmlns=""><span class="Bold">Gastrointestinal</span><br>[text]<br></p><p xmlns=""><span class="Bold">Genitourinary</span><br>[text]<br></p><p xmlns=""><span class="Bold">Hematologic</span><br>[text]<br></p><p xmlns=""><span class="Bold">Hepatic/Biliary/Pancreatic</span><br>[text]<br></p><p xmlns=""><span class="Bold">Immune</span><br>[text]<br></p><p xmlns=""><span class="Bold">Monitoring and Laboratory Tests</span><br>[text]<br></p><p xmlns=""><span class="Bold">Neurologic</span><br>[text]<br></p><p xmlns=""><span class="Bold">Ophthalmologic</span><br>[text]<br></p><p xmlns=""><span class="Bold">Peri-Operative Considerations</span><br>[Include information on management before, during and after surgery.]<br>[text]<br></p><p xmlns=""><span class="Bold">Psychiatric</span><br>[text]<br></p><p xmlns=""><span class="Bold">Renal</span><br>[text]<br></p><p xmlns=""><span class="Bold">Reproductive Health: Female and Male Potential</span><br>[Cross-reference to other relevant sections e.g. Pregnancy, Contraindications, Warnings and Precautions, contraception for both female and male]</p><ul xmlns=""><li><span class="Bold">Fertility</span><br>[Including infertility, female and male e.g. if there are no fertility data at all, this should be stated; sexually active men and women should use effective methods of contraception during treatment and up to six months after treatment for men, and one month after treatment for women.]<br>text</li><li><span class="Bold">Function</span><br>text</li><li><span class="Bold">Teratogenic Risk</span><br>text</li></ul><p xmlns=""><span class="Bold">Respiratory</span><br>[text]<br></p><p xmlns=""><span class="Bold">Sensitivity/Resistance</span><br>[text]<br></p><p xmlns=""><span class="Bold">Skin</span><br>[i.e. local or generalized reaction]<br>[text]</p><div class="Section" data-sectionCode="pi07.1" id="a63c33a5-e08a-472c-b8a2-a12dbc115f7a"><a name="a473c162-e176-44d0-bb97-2b7b6cf00e43"> </a><a name="section-4.7.1"> </a><p></p><h3 xmlns="">7.1 Special Populations</h3><div class="Section" data-sectionCode="pi07.1.1" id="a63c33a5-e08a-472c-b8a2-b12dbc115f7a"><a name="a473c162-e176-4ad0-b797-2b7b6cf00e43"> </a><a name="section-4.7.1.1"> </a><p></p><h4 xmlns="">7.1.1 Pregnant Women</h4><p xmlns="" class="First">[Include information related to Pregnancy Registries. The availability of a pregnancy exposure registry should also be included in the Patient Medication Information with a cross-reference to this section.</p><p xmlns="">If information on birth defects and miscarriage is available for the patient population for whom the drug is labelled, it must also be included.</p><p xmlns="">Include if applicable with appropriate section cross-reference e.g. dose adjustments during pregnancy and the postpartum period, maternal adverse reactions, fetal/neonatal adverse reactions, labour and delivery]</p><p xmlns="">Known or suspected effects on the child or mother, during pregnancy, labour and delivery, should be described here. For example:</p><p xmlns="">To date, limited exposure (&lt; 1,000 pregnancies) indicates that there is no detected risk, or shows limited exposure to &lt;drug&gt;, indicating low risk to mother and baby.]</p><p xmlns="">[text]<br>[The extent of exposure in pregnancy during clinical trials should be included:<br> Wide:        &gt; 1,000 pregnancies<br> Limited:      &lt; 1,000 pregnancies<br> Very Limited:  individual cases only<br> No experience]</p><p xmlns="">[The following or similar statement may be included:]</p><p xmlns="">Ideally, examinations using radiopharmaceuticals, especially those elective in nature of women of childbearing capability, should be performed during the first ten days following the onset of menses, or after ensuring the woman is not pregnant. The benefit of using a diagnostic radiopharmaceutical should be weighed against the possible risk to an embryo or a fetus.</p><p xmlns="">[text]</p></div><div class="Section" data-sectionCode="pi07.1.2" id="a63c33a5-e08a-472c-b8a2-b12dbd115f7a"><a name="a473c162-1176-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.7.1.2"> </a><p></p><h4 xmlns="">7.1.2 Breast-feeding</h4><p xmlns="" class="First">[text]</p><p xmlns="">[In the absence of human data, pertinent animal data should be included along with the following or similar statement:]</p><p xmlns="">It is unknown if [drug] is excreted in human milk. Caution should be exercised.</p><p xmlns="">[Unless studies have shown that the product is not excreted in human breast milk, the following or similar statement should be included. For example:</p><p xmlns="">Before administering a radioactive medicinal product to a mother who is breast feeding, consideration should be given as to whether the investigation could be reasonably delayed until the mother has ceased breast feeding as to whether the most appropriate choice of radiopharmaceutical has been made, bearing in mind the secretion of activity in breast milk. If the administration is considered necessary, breast feeding should be interrupted and the expressed feeds discarded.  It is usual to advise that breast feeding can be restarted when the level in the milk will not result in a radiation dose to the child greater that 1 mSv.]</p></div><div class="Section" data-sectionCode="pi07.1.3" id="a63c33a5-e08a-472c-b8c2-b12dbc115f7a"><a name="a473c162-e176-44d0-b787-2b7b6cf00e43"> </a><a name="section-4.7.1.3"> </a><p></p><h4 xmlns="">7.1.3 Pediatrics</h4><p xmlns="" class="First">[text]</p><p xmlns="">[In the absence of a Health Canada authorized pediatric indication, the following statement should be used:]</p><p xmlns=""><span class="Bold">Pediatrics [(age range)]:</span>Insufficient data are available therefore, Health Canada has not authorized an indication for pediatric use.</p></div><div class="Section" data-sectionCode="pi07.1.4" id="a63c33a5-e08a-472c-b8d2-b12dbc115f7a"><a name="a473c162-e176-44d0-b797-2b7b6df00e43"> </a><a name="section-4.7.1.4"> </a><p></p><h4 xmlns="">7.1.4 Geriatrics</h4><p xmlns="" class="First">[Experience in persons &gt;65 years of age is limited.]</p><p xmlns="">[text]</p></div></div></div><div class="Section" data-sectionCode="pi08" id="a63c33a5-e08a-472c-b8a2-b22dbc115f7a"><a name="a473c162-e176-44d0-b797-2b7b6cf11e43"> </a><a name="section-4.8"> </a><p></p><h2 xmlns="">8 ADVERSE REACTIONS</h2><div class="Section" data-sectionCode="pi08.1" id="a63c33a5-e08a-472c-b8a2-b12dbd215f7a"><a name="a473c162-e176-44d0-b797-2b7b6cf12e43"> </a><a name="section-4.8.1"> </a><p></p><h3 xmlns="">8.1 Adverse Reaction Overview</h3><p xmlns="" class="First">[Provide information on the most serious and/or most frequently occurring adverse reactions, or those where there have been reports of particularly severe cases. Frequencies to be stated as accurately as possible. It should not be a summary of the safety database.]</p><p xmlns="">[The most important serious adverse reactions associated with &lt;drug&gt; were infusion reactions [see 3 SERIOUS WARNINGS AND PRECAUTIONS], infectious events (see 15 MICROBIOLOGY, and hepatitis B reactivation [see 8.6 Post-Market Adverse Reactions].<br>
                                            or<br>[The most commonly reported adverse reactions (in adults/ pediatric patients) are nausea (34%), vomiting (22%), diarrhea (18%), and febrile neutropenia (0.4%).]   
                                        </p><p xmlns="">[A cross-reference to 7 WARNINGS AND PRECAUTIONS should be made if measures to be taken to avoid specific adverse reactions or actions to be taken if specific reactions occur are mentioned in section 7.]</p><p xmlns="">[Combination products: a statement at the beginning of this section pointing out which particular adverse reactions are usually attributed to which active substance of the combination, where known.]<br>[text]</p><div class="Section" data-sectionCode="pi08.1.1" id="a63c33a5-e08a-472e-b8c2-b12dbc115f7a"><a name="a473c162-e176-41d0-b787-2b7b6cf00e43"> </a><a name="section-4.8.1.1"> </a><p></p><h4 xmlns="">8.1.1 Immunogenicity</h4><p xmlns="" class="First">[Include a brief narrative describing the testing strategy for anti-drug antibodies (ADA) and the overall incidence of treatment-emergent or treatment-enhanced confirmed binding antibodies. For example:</p><p xmlns="">[Comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies, or to other &lt;drug name&gt; products may be misleading; or]</p><p xmlns=""> [As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.]<br>[text]</p></div></div><div class="Section" data-sectionCode="pi08.2" id="a63c33a5-e08a-473c-b8a2-b12dbd215f7a"><a name="a473c162-e176-44d0-b797-2b7b6cab0e43"> </a><a name="section-4.8.2"> </a><p></p><h3 xmlns="">8.2 Clinical Trial Adverse Reactions</h3><p xmlns="" class="First">Because clinical trials are conducted under very
                                            specific conditions, the adverse reaction rates observed
                                            in the clinical trials may not reflect the rates
                                            observed in practice and should not be compared to the
                                            rates in the clinical trials of another drug. Adverse
                                            reaction information from clinical trials is useful for
                                            identifying drug-related adverse events and for
                                            approximating rates.<br>[Include a brief
                                            description of data sources.]<br>[text]</p><a xmlns="" name="t8.2"></a><table xmlns="" width="100%" border="1"><caption><span>Table [#] [Title of
                                                Table]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule"></th><th class="Botrule Lrule Rrule Toprule">[drug name] n = [#] (%)</th><th class="Botrule Lrule Rrule Toprule">[placebo] n = [#] (%)</th></tr><tr><td class="Botrule Lrule Rrule Toprule">[categorize by system order class (SOC); then by decreasing frequency within each SOC; use MedDRA terms for headings, as applicable]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule"><span class="Bold">Cardiovascular</span><br>[text]<br><span class="Bold">Hepatic</span><br>[text]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="">[A brief narrative should follow the table to explain or supplement the information provided in the table where applicable. Separate tables may be required for different indications (e.g. oncology and a non-oncology indication) or different formulations (oral and intravenous)]</p><p xmlns="">[Adverse reactions may also be related to genetically determined product metabolism. Subjects or patients deficient in the specific enzyme may experience a different rate or severity of adverse reactions. This should be mentioned and where relevant correlated with data from clinical trials]<br>[text]</p><div class="Section" data-sectionCode="pi08.2.1" id="a63c45a5-e08a-472e-b8c2-b12dbc115f7a"><a name="a473c162-e176-41d0-b787-2b7bd4f00e43"> </a><a name="section-4.8.2.1"> </a><p></p><h4 xmlns="">8.2.1 Clinical Trial Adverse Reactions - Pediatrics (if applicable)</h4><p xmlns="" class="First">[Include (unless irrelevant) and describe: extend and age characteristics, any clinically relevant differences (i.e. seriousness or reversibility of adverse reaction) between safety profiles in adult and pediatric populations, or any relevant age groups, uncertainties due to limited experience. If the observed safety profile is similar in children and adults this could be stated.]</p></div></div><div class="Section" data-sectionCode="pi08.3" id="a63c33a5-e08a-473c-b8a2-b12dbd315f7a"><a name="a473c162-e146-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.8.3"> </a><p></p><h3 xmlns="">8.3 Less Common Clinical Trial Adverse Reactions</h3><p xmlns="" class="First">[Present as a list, categorized by System Organ Class, alphabetically: e.g.]<br>Cardiovascular: [text]<br>Gastrointestinal: [text]</p><div class="Section" data-sectionCode="pi08.3.1" id="a63c45a5-e08a-472e-b8c2-b12dbc115f1a"><a name="a473c162-e176-41d0-b787-2b7bd4f10e43"> </a><a name="section-4.8.3.1"> </a><p></p><h4 xmlns="">8.3.1 Less Common Clinical Trial Adverse Reactions - Pediatrics (if applicable)</h4><p xmlns="" class="First">[present as listed above if applicable]</p></div></div><div class="Section" data-sectionCode="pi08.4" id="a63c33a5-e08a-473c-b8a2-b22dbd215f7a"><a name="a473c162-e176-44d0-be97-2b7b6cf00e43"> </a><a name="section-4.8.4"> </a><p></p><h3 xmlns="">8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data</h3><div class="Section" data-sectionCode="pi08.4.1" id="a63ca5a5-e08a-472e-b8c2-b12dbc115f1a"><a name="a473c162-e176-41d0-b787-2b7bdaf10e43"> </a><a name="section-4.8.4.1"> </a><p></p><h4 xmlns="">8.4.1 Clinical Trial Findings</h4><p xmlns="" class="First">[outline any differences between adults and pediatrics as necessary with regard to abnormal laboratory findings]<br>[table]</p></div><div class="Section" data-sectionCode="pi08.4.2" id="a62ca5a5-e08a-472e-b8c2-b12dbc115f1a"><a name="a473c162-e176-41d0-b237-2b7bdaf10e43"> </a><a name="section-4.8.4.2"> </a><p></p><h4 xmlns="">8.4.2 Post-Market Findings</h4><p xmlns="" class="First">[outline any differences between adults and pediatrics as necessary with regard to post-market abnormal laboratory findings].<br>[table]</p></div></div><div class="Section" data-sectionCode="pi08.5" id="a63c33a5-e08a-473c-b8a2-b32dbd215f7a"><a name="a473c162-e176-44c0-b797-2b7b6cf00e43"> </a><a name="section-4.8.5"> </a><p></p><h3 xmlns="">8.5 Post-Market Adverse Reactions</h3><div class="Section" data-sectionCode="pi08.5.1" id="a63ca5a5-e08a-472e-b8c2-b12dbc995f1a"><a name="a473c162-e176-41d0-b787-2b799af10e43"> </a><a name="section-4.8.5.1"> </a><p></p><h4 xmlns="">8.5.1 Post-Market Adverse Reaction in Adults</h4><p xmlns="" class="First">[text and/or table]</p></div><div class="Section" data-sectionCode="pi08.5.2" id="a62ca5a5-e08a-472e-b8c2-b12d48115f1a"><a name="a473c162-e176-41d0-b237-2b7bdef10e43"> </a><a name="section-4.8.5.2"> </a><p></p><h4 xmlns="">8.5.2 Post-Market Adverse Reactions in Pediatrics (if applicable)</h4><p xmlns="" class="First">[text and/or table]</p></div></div></div><div class="Section" data-sectionCode="pi09" id="a63c33a5-e08a-483c-b8a2-b22dbd215f7a"><a name="a473c762-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.9"> </a><p></p><h2 xmlns="">9 DRUG INTERACTIONS</h2><div class="Section" data-sectionCode="pi09.1" id="a63c33a5-e08a-473c-b8a2-b14dbd315f7a"><a name="a473c162-e176-44d0-b797-2b7b6cf0de43"> </a><a name="section-4.9.1"> </a><p></p><h3 xmlns="">9.1 Drug Interactions Overview</h3><p xmlns="" class="First">The most important serious adverse reactions associated with &lt;drug&gt; were [ ].</p><p xmlns="">[For example co-administration with a CYY3A inhibitor, increased risk of cardiovascular accident (See 9.3 Drug-Drug Interactions)]</p><p xmlns="">[Provide information on the most serious and/or most frequently occurring interactions, or those where there have been reports of particularly severe cases. Frequencies to be stated as accurately as possible. It should not be a summary of the safety database.]</p></div><div class="Section" data-sectionCode="pi09.2" id="be75cfb9-3131-4903-800b-267527398a13"><a name="b9db4be0-3f46-437a-bd7b-4a3e01fadaad"> </a><a name="section-4.9.2"> </a><p></p><h3 xmlns="">9.2 Serious Drug Interactions Box</h3><p xmlns="" class="First">[In the absence of a serious drug interactions, maintain the heading but delete the box, and the following statement should be made:]</p><p xmlns="">At this time, no serious drug interactions have been identified.</p><table xmlns="" width="100%"><caption><span>Serious Drug Interactions</span></caption><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">[Serious (e.g., life-threatening) drug interactions should be highlighted in this box.  Not to exceed 20 lines.]</p><ul><li>[text]</li><li>[text]</li></ul></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi09.3" id="a63c56a5-e08a-473c-b8a2-b14dbd315f7a"><a name="a473c134-e176-44d0-b797-2b7b6cf0de43"> </a><a name="section-4.9.3"> </a><p></p><h3 xmlns="">9.3 Drug-Behavioural Risk</h3><p xmlns="" class="First">[e.g. alcohol use, obesity, sexual activity, smoking]<br>[text]</p></div><div class="Section" data-sectionCode="pi09.4" id="a63c33a5-e08a-473c-b8d2-b14dbd315f7a"><a name="a473c162-e176-44d0-b497-2b7b6cf00e43"> </a><a name="section-4.9.4"> </a><p></p><h3 xmlns="">9.4 Drug-Drug Interactions</h3><p xmlns="" class="First">The drugs listed in this table are based on
                                            either drug interaction case reports or studies, or
                                            potential interactions due to the expected magnitude and
                                            seriousness of the interaction (i.e., those identified
                                            as contraindicated).<br><br>[Lack of efficacy information with drug interactions belongs in this section.]<br><br>[or]<br><br>
                                            Interactions with other drugs have not been established. </p><a xmlns="" name="t11"></a><table xmlns="" width="100%"><caption><span>Table [#] - Established or Potential
                                                Drug-Drug Interactions</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Proper
                                                  /Common name</th><th class="Botrule Lrule Rrule Toprule">Source
                                                  of Evidence</th><th class="Botrule Lrule Rrule Toprule">Effect</th><th class="Botrule Lrule Rrule Toprule">Clinical comment</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[drug
                                                  A]</td><td class="Botrule Lrule Rrule Toprule">[level
                                                  of evidence, see legend]</td><td class="Botrule Lrule Rrule Toprule">[drug
                                                  A] conc</td><td class="Botrule Lrule Rrule Toprule">[Caution is warranted and therapeutic
                                                  concentration monitoring is recommended]</td></tr></tbody></table><p xmlns="">Legend: C = Case Study; CT = Clinical Trial; T =
                                            Theoretical</p></div><div class="Section" data-sectionCode="pi09.5" id="a63c33a5-e0aa-473c-b8a2-b14dbd315f7a"><a name="a273c162-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-4.9.5"> </a><p></p><h3 xmlns="">9.5 Drug-Food Interactions</h3><p xmlns="" class="First">[e.g. citrus, daily]<br>[text]</p></div><div class="Section" data-sectionCode="pi09.6" id="a63c33a5-e08a-47bc-b8d2-b14dbd315f7a"><a name="a473c162-e176-44d0-b997-2b7b6cf00e43"> </a><a name="section-4.9.6"> </a><p></p><h3 xmlns="">9.6 Drug-Herb Interactions</h3><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi09.7" id="be78cfb9-3131-4903-800b-267527398a13"><a name="b9db4be0-3f46-437a-bd7b-4a3e01aadaad"> </a><a name="section-4.9.7"> </a><p></p><h3 xmlns="">9.7 Drug-Laboratory Test Interactions</h3><p xmlns="" class="First">[e.g. steroid, corticosteroids]<br>[text]</p></div></div><div class="Section" data-sectionCode="pi10" id="fa324c26-b939-4c3a-901d-516ccc314522"><a name="dc0d2dd9-1c53-49dc-bad3-d6b420d064e9"> </a><a name="section-4.10"> </a><p></p><h2 xmlns="">10 ACTION AND CLINICAL PHARMACOLOGY</h2><div class="Section" data-sectionCode="pi10.1" id="f7a324c26-b939-4c3a-901e-516ccc314522"><a name="ac0d2dd9-1c53-49dc-bad3-d6b420d064e9"> </a><a name="section-4.10.1"> </a><p></p><h3 xmlns="">10.1 Mechanism of Action</h3><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi10.2" id="da324c26-b939-4d3a-901e-516ccc314522"><a name="cc0d2dd9-1c53-49dc-bad3-d6b420dc64e9"> </a><a name="section-4.10.2"> </a><p></p><h3 xmlns="">10.2 Pharmacodynamics</h3><p xmlns="" class="First">[In some cases a pharmacodynamic (PD) marker may be used in lieu of clinical endpoints or as additional support for similarity. If this is the case, insert a comparative PD section with a brief narrative describing the study and a tabulation of the PD results including the appropriate statistical analyses].</p><p xmlns="">[text]<br>[table]</p></div><div class="Section" data-sectionCode="pi10.3" id="aaa324c26-b939-4d4a-901e-516ccc314522"><a name="cc0d2dd9-1c53-49dc-bad3-d6b320d064e9"> </a><a name="section-4.10.3"> </a><p></p><h3 xmlns="">10.3 Pharmacokinetics</h3><a xmlns="" name="t12"></a><table xmlns="" width="100%"><caption><span>Table [#] - Summary of [proper name]
                                                Pharmacokinetic Parameters in [specific patient
                                                population]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule"></th><th class="Botrule Lrule Rrule Toprule">C<span class="Sub">max</span></th><th class="Botrule Lrule Rrule Toprule">T<span class="Sub">max</span></th><th class="Botrule Lrule Rrule Toprule">t<span class="Sub">1/2</span>(h)</th><th class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">0=∞</span></th><th class="Botrule Lrule Rrule Toprule">CL</th><th class="Botrule Lrule Rrule Toprule">Vd</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">Single
                                                  dose mean</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="" class="First"><span class="Bold">Absorption</span><br>[text]</p><p xmlns=""><span class="Bold">Distribution</span><br>[text]</p><p xmlns=""><span class="Bold">Metabolism</span><br>[text]</p><p xmlns=""><span class="Bold">Elimination</span><br>[text]</p><p xmlns=""><span class="Bold">Special Populations and Conditions</span><br>[text]</p><p xmlns=""><span class="Bold">Pediatrics</span><br>[text]</p><p xmlns=""><span class="Bold">Geriatrics</span><br>[text]</p><p xmlns=""><span class="Bold">Gender</span><br>[text]</p><p xmlns=""><span class="Bold">Pregnancy and Breast-feeding</span><br>[text]</p><p xmlns=""><span class="Bold">Genetic Polymorphism</span><br>[text]</p><p xmlns=""><span class="Bold">Ethnic origin</span><br>[text]</p><p xmlns=""><span class="Bold">Hepatic Insufficiency</span><br>[text]</p><p xmlns=""><span class="Bold">Renal Insufficiency</span><br>[text]</p><p xmlns=""><span class="Bold">Obesity</span><br>[text]</p></div></div><div class="Section" data-sectionCode="pi11" id="da324d26-c939-443a-901e-526dcc314522"><a name="cc0d2dd9-1c53-49dc-bad3-d6b420d069e9"> </a><a name="section-4.11"> </a><p></p><h2 xmlns="">11 STORAGE, STABILITY AND DISPOSAL</h2><p xmlns="" class="First">[Recommended storage conditions for each dosage form as supported by stability studies; </p><p xmlns="">For reconstituted products, including parenterals, the recommended storage period and conditions should be stated (e.g. do not store above 25°C, protect from light); any know incompatibilities including those between drugs, diluents or infusion fluids etc.</p><p xmlns="">Disposal instructions should be included for all drug products – include a cross-reference to more detailed safe disposal instructions under Special Handling Instruction section as applicable.]</p><p xmlns="">[text]</p></div><div class="Section" data-sectionCode="pi12" id="bba325d26-c939-443a-901e-526dcc314522"><a name="fc0d2dd9-1c53-49dc-bad3-d6b420d064e9"> </a><a name="section-4.12"> </a><p></p><h2 xmlns="">12 SPECIAL HANDLING INSTRUCTIONS</h2><p xmlns="" class="First">[Any special handling instructions and cautionary statements for people who are likely to come into contact with potentially hazardous products during storage, handling, preparation, administration and disposal of cytotoxic or hazardous drug should be clearly specified (e.g. handling by women who are pregnant or breast feeding). Include special instructions for decontamination and safe disposal of drugs and associated material (e.g. all radioactive products should be appropriately shielded, use of personal protective equipment (PPE), flow hoods, toilet should be flushed several times after use]<br>[text]</p></div></div></div></div><div class="card mb-2 pb-2" id="d91389e0-c234-44d9-8327-91b121723a8f"><h5 class="card-header text-white bg-aurora-accent1">PART II: SCIENTIFIC INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="pii00" id="ab6a947eb-e2be-45c0-8b2e-15d0d0eebed8"><a name="d91389e0-c234-44d9-8327-91b121723a8f"> </a><a name="section-5"> </a><p></p><h1 xmlns="">PART II: SCIENTIFIC INFORMATION</h1><div class="Section" data-sectionCode="pii13" id="ee2875272-8229-4c12-919e-827854dcd76a"><a name="d134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-5.1"> </a><p></p><h2 xmlns="">13 PHARMACEUTICAL INFORMATION</h2><p xmlns="" class="First"><span class="Bold">Drug Substance</span><br><br>Proper name: [text]<br><br> Chemical name: [text]<br><br> Molecular formula and molecular mass: [text]<br><br>Structural
                                    formula: [image]<br><img alt="chemical structure" src="structure.jpg"><br><br>
                                    Physicochemical properties: [text]</p><p xmlns=""><span class="Bold">Product Characteristics</span><br>[text]</p><p xmlns=""><span class="Bold">Viral Inactivation</span><br>[text]</p><p xmlns="">[For products derived from plasma, detail the viral reduction steps. Include information on selection criteria for donors, if applicable.]</p></div><div class="Section" data-sectionCode="pii14" id="ab2875272-8229-4c12-919e-827854ddd76a"><a name="c134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-5.2"> </a><p></p><h2 xmlns="">14 CLINICAL TRIALS</h2><p xmlns="" class="First">[Clinical trial information for innovator or comparative trials for similar biological, or "biosimilar" medicine that is similar to another biological medicine that has already been authorised for use. For biosimilars, the information should be consistent with the reference medicinal product; any differences with the reference medicinal product should be justified.]</p><p xmlns="">[For product monographs with multiple indications, the Trial Design and Study Demographics, and Study Results tables should be replicated for each approved indication]</p><div class="Section" data-sectionCode="pii14.1" id="a2875272-8229-4c12-919e-827854ddd78a"><a name="e134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-5.2.1"> </a><p></p><h3 xmlns="">14.1 Trial Design and Study Demographics</h3><a xmlns="" name="t14.1"></a><table xmlns="" width="100%"><caption><span>Table [#] - Summary of patient demographics for
                                                clinical trials in [specific indication]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Study
                                                  #</th><th class="Botrule Lrule Rrule Toprule">Trial
                                                  design</th><th class="Botrule Lrule Rrule Toprule">Dosage, route of administration and duration</th><th class="Botrule Lrule Rrule Toprule">Study
                                                  subjects (n)</th><th class="Botrule Lrule Rrule Toprule">Mean
                                                  age (Range)</th><th class="Botrule Lrule Rrule Toprule">Sex</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td></tr></tbody></table><p xmlns="" class="First">[Provide a brief narrative describing the demographic characteristics of the study population:]<br>[text]</p></div><div class="Section" data-sectionCode="pii14.2" id="a2875272-8229-4a12-919e-827854ddd78a"><a name="a134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-5.2.2"> </a><p></p><h3 xmlns="">14.2 Study Results</h3><a xmlns="" name="t14.2"></a><table xmlns="" width="100%"><caption><span>Table [#] - Results of study [#] in [specific
                                                indication]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Primary Endpoints</th><th class="Botrule Lrule Rrule Toprule">Associated value and statistical significance for
                                                  Drug at specific dosages</th><th class="Botrule Lrule Rrule Toprule">Associated value and statistical significance for
                                                  Placebo or active control</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td></tr></tbody></table></div><div class="Section" data-sectionCode="pii14.3" id="df2875272-8229-4c12-919e-827954ddd78a"><a name="c134d52c-f9d4-4698-a012-84b29ee3d95a"> </a><a name="section-5.2.3"> </a><p></p><h3 xmlns="">14.3 Comparative Bioavailability Studies</h3><p xmlns="" class="First">[Provide a narrative outlining the design of the bioequivalence study. The values in the table should be based on the measured data from the study. No potency correction should be applied]</p><p xmlns="">[There should be no claims of bioequivalence or clinical equivalence between the biosimilar and the reference biologic drug.]<br>[text]</p><a xmlns="" name="t15"></a><table xmlns="" width="100%"><caption><span>Table for single dose studies</span></caption><tfoot><tr><td colspan="0" align="left"><dl class="Footnote"><dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt><dd>Identity of the test
                                                  product.</dd><dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt><dd>Identity of the reference
                                                  product, including the manufacturer, and origin
                                                  (country of purchase).</dd><dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt><dd>Indicate %
                                                  Confidence Interval (i.e., 90% or 95%) in the
                                                  column heading and list for the AUCT, AUCI and
                                                  CMAX (if required).</dd><dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt><dd>For drugs with a
                                                  half-life greater than 24 hours AUCT should be
                                                  replaced with AUC0-72.</dd><dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt><dd>Expressed as either
                                                  the arithmetic mean (CV%) or the median (range)
                                                  only.</dd><dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt><dd>Expressed as the
                                                  arithmetic mean (CV%) only.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule" colspan="5">Analyte Name<br>(__x__mg)<br>From measured data<br>Geometric Mean<br>Arithmetic Mean(CV %)</th></tr><tr><th class="Botrule Lrule Rrule Toprule">Parameter</th><th class="Botrule Lrule Rrule Toprule">Test<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></th><th class="Botrule Lrule Rrule Toprule">Reference<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></th><th class="Botrule Lrule Rrule Toprule">%
                                                  Ratio of Geometric Means</th><th class="Botrule Lrule Rrule Toprule">Confidence Interval<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></th></tr><tr><td class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">T</span>(units)<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">I</span>(units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">C<span class="Sub">MAX</span>(units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">T<span class="Sub">MAX</span>(h)<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule">Not applicable</td><td class="Botrule Lrule Rrule Toprule">Not applicable</td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">T<span class="Sub">1/2</span>(h)<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule">Not applicable</td><td class="Botrule Lrule Rrule Toprule">Not applicable</td></tr></tbody></table><a xmlns="" name="t16"></a><table xmlns="" width="100%"><caption><span>Table for multiple dose studies</span></caption><tfoot><tr><td colspan="0" align="left"><dl class="Footnote"><dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt><dd>Identity of the test
                                                  product.</dd><dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt><dd>Identity of the reference
                                                  product, including the manufacturer, and origin
                                                  (country of purchase),where
                                                  applicable.</dd><dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt><dd>Indicate %
                                                  Confidence Interval (i.e., 90% or 95%) in the
                                                  column heading and list for the AUCT, AUCI and
                                                  CMAX (if required).</dd><dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt><dd>For drugs with
                                                  a half-life greater than 24 hours AUCT should be
                                                  replaced with AUC0-72.</dd><dt><a name="footnote-11" href="#footnote-reference-11">¶</a></dt><dd>Expressed as either
                                                  the arithmetic mean (CV%) or the median (range)
                                                  only.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule" colspan="5">Analyte Name<br>(__x__mg)<br>From measured data<br>Geometric Mean<br>Arithmetic Mean(CV %)
                                                    </th></tr><tr><th class="Botrule Lrule Rrule Toprule">Parameter</th><th class="Botrule Lrule Rrule Toprule">Test<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></th><th class="Botrule Lrule Rrule Toprule">Reference<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></th><th class="Botrule Lrule Rrule Toprule">%
                                                  Ratio of Geometric Means</th><th class="Botrule Lrule Rrule Toprule">Confidence Interval<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a></th></tr><tr><td class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">tau</span>(units)<a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">C<span class="Sub">MAX</span>(units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">C<span class="Sub">MIN</span>(units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">T<span class="Sub">MAX</span>(h)<a name="footnote-reference-11" href="#footnote-11" class="Sup">¶</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule">Not applicable</td><td class="Botrule Lrule Rrule Toprule">Not applicable</td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pii15" id="a2875272-8229-4c12-a19e-827954ddd78a"><a name="e134d52c-f1d4-4698-a082-84b29ee3d95a"> </a><a name="section-5.3"> </a><p></p><h2 xmlns="">15 MICROBIOLOGY</h2><p xmlns="" class="First">[text]<br>[table]<br>[in the absence of microbiological information include the following statement:]<br>No microbiological information is required for this product</p></div><div class="Section" data-sectionCode="pii16" id="a42a7572-8229-4c12-a19e-827954ddd78a"><a name="c134d52c-f9d4-4698-a082-84b29ee3a95a"> </a><a name="section-5.4"> </a><p></p><h2 xmlns="">16 NON-CLINICAL TOXICOLOGY</h2><p xmlns="" class="First">[Narrative where possible. Include a table only where presentation is made more concise, e.g. no long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether &lt;drug&gt; affects fertility in females or males, there may be increased risk to chromosome damage.]<br>[text]</p></div><div class="Section" data-sectionCode="pii17" id="ef8a4d48-0fc3-4e44-b4b6-550140d4de5d"><a name="be74b6e6-c431-4a5f-a18e-ed3214381456"> </a><a name="section-5.5"> </a><p></p><h2 xmlns="">17 SUPPORTING PRODUCT MONOGRAPHS</h2><p xmlns="" class="First">[List only Health Canada authorized product monographs that were supportive in the development of the product monograph e.g. Canadian Reference Product for a generic or biosimilar product, combination product, or subsequent entry product.  Where there are no such supporting product monographs, this section should be omitted.]</p><p xmlns="">[numbered list:]<br>[Brand name] [(dosage form, strength)], submission control [number], Product Monograph, [sponsor]. [(MON, DD, YYYY)]</p></div></div></div></div><div class="card mb-2 pb-2" id="be74b6e6-c461-4a5f-a18e-ed321b381456"><h5 class="card-header text-white bg-aurora-accent1">PATIENT MEDICATION INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="pmi00" id="baa4d498-0fc3-4e44-b4b6-550140d4de5d"><a name="be74b6e6-c461-4a5f-a18e-ed321b381456"> </a><a name="section-6"> </a><p></p><h1 xmlns="">PATIENT MEDICATION INFORMATION</h1><div class="Section" data-sectionCode="pmi01" id="ea4ec98b-b2d3-4d73-877c-aaa5eb28997d"><a name="067c0a3b-5869-43a7-baff-ce6de72ae1e5"> </a><a name="section-6.1"> </a><p></p><h2 xmlns="">READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE</h2><p xmlns="" class="First"><span class="Bold">[BRAND NAME]</span></p><p xmlns=""><span class="Bold">[Proper Name in Final Dosage Form]</span></p><p xmlns="">Read this carefully before you start taking <span class="Bold">[Brand
                                    name]</span>
                                    and each time you get a refill. This leaflet is a summary and
                                    will not tell you everything about this drug. Talk to your
                                    healthcare professional about your medical condition and
                                    treatment and ask if there is any new information about <span class="Bold">[Brand
                                    name]</span>.</p><p xmlns="">[delete this box if there are no Serious Warnings and Precautions]</p><p xmlns="">[if applicable, the box should contain a plain language version of the information provided in the Serious Warnings and Precautions box in Part I]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First"><td class="Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Serious Warnings and
                                                  Precautions</span></td></tr><tr class="Last"><td class="Botrule Lrule Rrule"><ul><li>[text]</li><li>[text]</li></ul></td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi02" id="baa4d498-0gc3-4e44-bcb6-550140d4de5d"><a name="be74b6e6-1431-4a5f-a18e-ed321b381456"> </a><a name="section-6.2"> </a><p></p><h2 xmlns="">What is [Brand name] used for?</h2><ul xmlns=""><li>[text]</li><li>[text]</li></ul></div><div class="Section" data-sectionCode="pmi03" id="bca4d498-0gc3-4e44-bcb6-550140d4de5d"><a name="be74b6e6-c431-4adf-a18e-ed321b381456"> </a><a name="section-6.3"> </a><p></p><h2 xmlns="">How does [Brand name] work?</h2><p xmlns="" class="First">[At the grade 6-8 reading level, explain the mechanism of
                                    action, in one or two sentences. Indicate how long it takes to
                                    work and how to know if it is working.]</p><p xmlns="">[text]</p></div><div class="Section" data-sectionCode="pmi04" id="bca4d498-0gc3-4e44-bcb6-55013024de5d"><a name="be74b6e6-c431-4a5f-a18e-ed321b381756"> </a><a name="section-6.4"> </a><p></p><h2 xmlns="">What are the ingredients in [Brand name]?</h2><p xmlns="" class="First">Medicinal ingredients: [List all medicinal ingredients
                                    from Part I.]</p><p xmlns="">Non-medicinal ingredients: [List all non-medicinal
                                    ingredients in alphabetical order from Part I.]</p></div><div class="Section" data-sectionCode="pmi05" id="bca4d498-0gc3-4e54-bcb6-550130d4de5d"><a name="be74b6e6-c431-4a5f-a18e-ed3a1b381456"> </a><a name="section-6.5"> </a><p></p><h2 xmlns="">[Brand name] comes in the following dosage forms:</h2><p xmlns="" class="First">[To maintain brevity, this is the only information
                                    required in this section.]</p><p xmlns="">[dosage form(s) and strength(s)]</p></div><div class="Section" data-sectionCode="pmi06" id="bca4c498-00c3-4e44-bcb6-550134d4de5d"><a name="be74b6e6-cd31-4a5f-a18e-ed321b381456"> </a><a name="section-6.6"> </a><p></p><h2 xmlns="">Do not use [Brand name] if:</h2><p xmlns="" class="First">[Enter one point for each contraindication from Part
                                    I.]</p><ul xmlns=""><li>[text]</li><li>[text]</li></ul></div><div class="Section" data-sectionCode="pmi07" id="b6b37351-bbc9-46d9-b148-27ba3cb0a75e"><a name="be74b6e6-c431-4a5f-a18e-ed32cc381456"> </a><a name="section-6.7"> </a><p></p><h2 xmlns="">To help avoid side effects and ensure proper use, talk to your healthcare professional before you take [Brand name]]. Talk about any health conditions or problems you may have, including if you:</h2><p xmlns="" class="First">[Enter one point for each warning and precaution from
                                    Part I.]</p><ul xmlns=""><li>[text]</li><li>[text]</li></ul></div><div class="Section" data-sectionCode="pmi08" id="edac0d6f-3c91-48b5-99c0-e0f940925d37"><a name="be74bbe6-c431-4a5f-a18e-ed321b381456"> </a><a name="section-6.8"> </a><p></p><h2 xmlns="">Other warnings you should know about:</h2><p xmlns="" class="First">[Enter general information that would not appear in the
                                    serious warnings and precautions box or other existing headings.
                                    Otherwise this heading is not required.]</p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Tell your healthcare professional about all the medicines
                                    you take, including any drugs, vitamins, minerals, natural
                                    supplements or alternative medicines.</span></p></div><div class="Section" data-sectionCode="pmi09" id="bca4c498-0ac3-4e44-bcb6-550134d4de5d"><a name="be74b6e6-c431-4a5f-a18e-ed321ab81456"> </a><a name="section-6.9"> </a><p></p><h2 xmlns="">The following may interact with [Brand name]:</h2><ul xmlns=""><li>[list]</li></ul></div><div class="Section" data-sectionCode="pmi10" id="e23321cd-5111-4aa3-b650-74f93bcda261"><a name="be74b6e6-c431-4a5f-a18e-ed3212281456"> </a><a name="section-6.10"> </a><p></p><h2 xmlns="">How to take [Brand name]:</h2><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pmi11" id="cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7"><a name="be74b6e6-c431-4a5f-a18e-11321b381456"> </a><a name="section-6.11"> </a><p></p><h2 xmlns="">Usual dose:</h2><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pmi12" id="beaaa5b8-6693-4d4c-a897-fa5c9562b1be"><a name="be74b6e6-c431-4a5f-a18e-ed321b311456"> </a><a name="section-6.12"> </a><p></p><h2 xmlns="">Overdose:</h2><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">If you think
                                                you have taken too much [Brand name], contact your
                                                healthcare professional, hospital emergency
                                                department or regional poison control centre
                                                immediately, even if there are no symptoms.</td></tr></tbody></table><p xmlns="">[The boxed message may be modified to provide the most
                                    appropriate advice according to current standards of care for
                                    this drug product.]</p></div><div class="Section" data-sectionCode="pmi13" id="ffd59b8d-fe66-4d86-a54f-0613d4168199"><a name="be74b6e6-c431-4a5f-a18e-ed321e381456"> </a><a name="section-6.13"> </a><p></p><h2 xmlns="">Missed dose:</h2><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pmi14" id="cb61f530-b95a-4047-b8ea-861c5a7a05e8"><a name="be74b6e6-c431-4a5f-a98e-ed321b381456"> </a><a name="section-6.14"> </a><p></p><h2 xmlns="">What are possible side effects from using [Brand name]?</h2><p xmlns="" class="First">These are not all the possible side effects you may feel
                                    when taking [Brand name]. If you experience any side effects not
                                    listed here, contact your healthcare professional.</p><p xmlns="">[text]</p><p xmlns="">[Self-limiting side effects should be described in the text section only. Serious side effects must be listed in the serious side effects table.  Each side effect should appear only once, in text or in the table to avoid duplication.]</p><a xmlns="" name="t8"></a><table xmlns="" width="100%" border="1"><caption><span>Serious side effects and what to do about
                                        them</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule" rowspan="2">Symptom / effect</th><th class="Botrule Lrule Rrule Toprule" colspan="2" align="center">Talk to your healthcare
                                                professional</th><th class="Botrule Lrule Rrule Toprule" rowspan="2">Stop taking drug and get immediate medical
                                                help</th></tr><tr><th class="Botrule Lrule Rrule Toprule">Only if
                                                severe</th><th class="Botrule Lrule Rrule Toprule">In all
                                                cases</th></tr><tr><td class="Botrule Lrule Rrule Toprule"><span class="Bold">VERY COMMON</span><br>
                                                [Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition:
                                                symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule"><span class="Bold">COMMON</span><br>[Condition:
                                                symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition:
                                                symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule"><span class="Bold">RARE</span><br>[Condition:
                                                symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[Condition:
                                                symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="">If you have a troublesome symptom or side effect that is
                                    not listed here or becomes bad enough to interfere with your
                                    daily activities, talk to your healthcare
                                    professional.</p><p xmlns="">[Please choose the following reporting box option which is most appropriate for this product.]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First"><td class="Bold Lrule Rrule Toprule">Reporting Side
                                                Effects</td></tr><tr class="Last"><td class="Botrule Lrule Rrule"><p class="First"><br>You can report any suspected side effects
                                                  associated with the use of health products to
                                                  Health Canada by:</p><ul class="Unordered"><li>Visiting the Web page on Adverse Reaction
                                                  Reporting <a href="http://www.hc-sc.gc.ca/dhp-                                                             mps/medeff/report-declaration/index-eng.php">(http://www.hc-sc.gc.ca/dhp-
                                                  mps/medeff/report-declaration/index-eng.php)</a>
                                                  for information on how to report online, by mail
                                                  or by fax; or</li><li>Calling toll-free at 1-866-234-2345.</li></ul></td></tr></tbody></table><table xmlns="" width="100%"><tbody class="Headless"><tr class="First"><td class="Bold Lrule Rrule Toprule">Reporting Suspected Side
                                                Effects</td></tr><tr class="Last"><td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><br>For the general public: </span>Should you experience a side effect following immunization, please report it to your doctor, nurse, or pharmacist.</p><p><br>Should you require information related to the management of the side effect, please contact your healthcare provider. The Public Health Agency of Canada, Health Canada and [Sponsor Name] cannot provide medical advice.</p><p><span class="Bold"><br>For healthcare professionals: </span>If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory <a href="http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng.php">(http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng.php)</a> and send it to your local Health Unit.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi15" id="c9d75711-2ce9-451e-aa51-91026ec1555e"><a name="be74b6e6-c431-4a5f-a18e-ed321b081456"> </a><a name="section-6.15"> </a><p></p><h2 xmlns="">Storage:</h2><p xmlns="" class="First">[text]</p><p xmlns="">Keep out of reach and sight of children.</p></div><div class="Section" data-sectionCode="pmi16" id="f6693e7a-21c9-492f-833b-4e8f3911d3a5"><a name="be74b6e6-c431-4a5f-a18e-ed321b381446"> </a><a name="section-6.16"> </a><p></p><h2 xmlns="">If you want more information about [Brand name]:</h2><ul xmlns=""><li>Talk to your healthcare professional</li><li>Find the full product monograph that is prepared for
                                        healthcare professionals and includes this Patient
                                        Medication Information by visiting the Health Canada
                                        website <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html">(https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html)</a>; the
                                        manufacturer's website [website], or by calling 1-800-[phone
                                        number].</li></ul><p xmlns="" class="First">This leaflet was prepared by [Sponsor Name]</p><p xmlns="">Last Revised (MON-DD-YYYY)</p></div></div></div></div><div class="hide-in-screen force-page-break-before card spl" id="print-product-details"><h2>PRODUCT DETAILS</h2><div class="spl"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Market Authorization Holder -&nbsp;</span>Acme Pharma Inc. (1111)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>9526 Columbia St.</td></tr><tr><td>Hanover Park,&nbsp;Illinois,&nbsp;60133</td></tr><tr><td>UNITED STATES OF AMERICA (THE)</td></tr></table></td><td class="formItem"><div>Tel: +12025550178</div><div>Email: test@canada.ca</div><div>Web: http://www.test.ca</div></td></tr></table><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Canadian Importer/Distributor -&nbsp;</span>Acme Distributing Ltd. (0000)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>250 Lanark Ave.</td></tr><tr><td>Ottawa,&nbsp;Ontario,&nbsp;K1Z 6R5</td></tr><tr><td>CANADA</td></tr></table></td><td class="formItem"><div>Tel: +14165550134</div><div>Email: test.2@canada.ca</div><div>Web: http://www.test.ca</div></td></tr></table><section><div class="Section"><p></p><h2>PRODUCT #1 LORUM IPSUM POWDER 
		(ACETAMINOPHEN), 		
		ACETAMINOPHEN&nbsp;
			1&nbsp;								
			MG&nbsp;
		POWDER FOR ORAL SOLUTION</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM POWDER&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen powder for oral solution</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM POWDER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">65432551</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">SUBCUTANEOUS USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">POWDER FOR ORAL SOLUTION</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">1&nbsp;								
			mg&nbsp;in&nbsp;5&nbsp;mL</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (OFF WHITE)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">THYROID AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1212<br><br><br></td><td class="formItem">1 &nbsp;in&nbsp;1 BOX<br>2 &nbsp;in&nbsp;1 TRAY<br>5 mL&nbsp;in&nbsp;1 VIAL<br></td><td class="formItem">APPROVED<br><br><br></td><td class="formItem">2018-06-01<br><br><br></td><td class="formItem"><br><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section></div></div></div></div></div></main></div></div>
<script src="https://code.jquery.com/jquery-3.4.1.slim.min.js" integrity="sha384-J6qa4849blE2+poT4WnyKhv5vZF5SrPo0iEjwBvKU7imGFAV0wwj1yYfoRSJoZ+n" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.0/dist/umd/popper.min.js" integrity="sha384-Q6E9RHvbIyZFJoft+2mJbHaEWldlvI9IOYy5n3zV9zzTtmI3UksdQRVvoxMfooAo" crossorigin="anonymous"></script>
<script src="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/js/bootstrap.min.js" integrity="sha384-wfSDF2E50Y2D1uUdj0O3uMBJnjuUD4Ih7YwaYd1iqfktj0Uod8GCExl3Og8ifwB6" crossorigin="anonymous"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/stickyfill/2.0.5/stickyfill.min.js"></script>
		<script xmlns="http://www.w3.org/1999/xhtml">
			try {
			  var elements = document.querySelectorAll('.sticky');
			  Stickyfill.add(elements);
			} catch (e) {
			  console.log(e)
			}
			
			// Mitigate IE/Edge bug showing bullets on lists which are hidden when loading the page
			$(document).ready(function(){
				if (document.documentMode || /Edge/.test(navigator.userAgent)) {
					$('ul:hidden').each(function(){
						$(this).parent().append($(this).detach());
					});
				}
			});			
		</script></body></html>